Median time to treatment response in patients with moderate-to-severe plaque psoriasis treated with brodalumab 210 mg or ustekinumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3)

Background: Brodalumab is a human monoclonal antibody that binds to and blocks IL-17RA, the receptor subunit shared by the pro-inflammatory cytokines IL-17A, IL-17F, and IL-17A/F. While results from phase 3 studies demonstrated high degrees of efficacy for brodalumab in the treatment of moderate-to-severe plaque psoriasis, also important is its speed of response compared to ustekinumab.

http://ift.tt/2snXASk